Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDY-5301 in Anterior STEMI (IOCYTE AMI-3)
NCT04837001Phase 3Completed
- Sponsor
- Faraday Pharmaceuticals
- Start
- May 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing FDY-5301 with Placebo (2 arms). Primary endpoint: Proportion of either cardiovascular mortality or heart failure at Month 12. Started May 2022; status: completed.
02
Drugs
Sodium iodide
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04837001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837001.